A Multicenter, Open-label Study to Determine the Effects of Lacosamide on Sleep in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

July 31, 2012

Study Completion Date

July 31, 2012

Conditions
Healthy Subjects
Interventions
DRUG

Lacosamide

Lacosamide will be given orally in 50 mg tablets twice a day for 7 days. The dose will increase weekly by 100 mg per day to a target dose of 300 mg per day. Once the target dose of 300 mg per day has been achieved for 9 days, a 2-day tapering of Lacosamide will occur by 100 mg per day.

Trial Locations (4)

Unknown

005, Little Rock

003, Cleveland

004, Austin

001, Fredericksburg

Sponsors

Lead Sponsor

All Listed Sponsors
lead

UCB Pharma

INDUSTRY